Tag Archives: Forbes

John Lechleiter Forbes Op-Ed: Debunking the Five Big Myths About ‘Big Pharma’


This week, Eli Lilly and Company President, Chairman and CEO John Lechleiter refutes five big myths about big pharma in this Forbes opinion piece. He points to these five biggest industry myths as ‘routinely poisoning debates, obscuring genuine problems, and distorting policy recommendations on health care.’ In short (excerpts): Myth #1 Pharmaceutical companies exaggerate the costs of developing new medicines to justify high prices. In fact: The research and development (R&D) expenditures of this industry Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The Perfect Close


With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at 5,008.10, marking the third day in history with a close above 5,000. Since 95% of US publicly traded biotech companies are listed on the Nasdaq exchange, the team at BIO couldn’t help but join the excitement. Back in 2000, the Nasdaq index was flourishing with dot coms. At that point there was no Facebook or Netflix and Google wasn’t public. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Forbes Asks: Should Economists Perform Surgery and Doctors Conduct Economic Policy?


Over at Forbes, University of Chicago economist Tomas Philipson has an insightful post analyzing several of the arguments frequently made in recent debates about the price and value of innovative medicines. Philipson argues that physicians are often self-interested as buyers when complaining about drug prices, and often fail to understand the broader economic context in which drug pricing decisions must be made: “Just as you wouldn’t let a financial planner perform cancer surgery, we shouldn’t Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Op-Ed in Forbes on the Threat to Philanthropy


This week, Howard Husock extols the benefits of venture philanthropy through this Forbes op-ed. In the op-ed, Husock points out that private entities conduct a significant portion of applied research toward new drug development as referenced in this 2008 Manhattan Institute paper, “The Truth About Drug Innovation”, co-authored by two researchers from the Tufts University Center for the Study of Drug Development, and Institute Fellow Benjamin Zycher: “. . .among. . . thirty-five drugs and Read More >

Business and Investments, Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Forbes profiles a medical miracle and the value of cures


This week, Forbes’ Matthew Herper wrote a moving story about a girl who is a medical miracle at only 5-years-old. When Evie Elsaesser was born, she was only expected to live a few hours as her bones were soft and un-calcified. Shortly afterwards, Evie was enrolled in a clinical trial for a drug that replaced the bone-forming enzyme that she was missing. While she suffered from side effects and endured a long road to being Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,